Ontology type: schema:ScholarlyArticle
2021-03-13
AUTHORS ABSTRACTPurpose of ReviewAtrial fibrillation (AF) is a chronic and progressive disorder, associated with effort intolerance, impairments in quality of life, and reduced survival. In patients with symptomatic atrial fibrillation, pulmonary vein isolation is an important treatment modality to reduce recurrent arrhythmia and improve quality of life. The purpose of this paper is to review practical considerations of the cryoballoon ablation procedure in order to minimize the risk of adverse procedural outcomes and arrhythmia recurrences.Recent FindingsEmerging evidence with respect to cryoablation dosing has beneficially refined the cryoballoon ablation procedure. In aggregate, dose limitation can be achieved by the following: (1) If real-time pulmonary vein potential (PVP) monitoring is feasible, an early time to isolation (TTI, e.g., < 0–60 s) suggests that the “bonus freeze” may be omitted; (2) In PVs where real-time PVP monitoring is feasible, a late TTI (e.g., >60–90 s) or a balloon temperature warmer than −35 °C at 60 s suggests that the lesion be abandoned and the balloon repositioned; (3) The minimum cryoablation duration should be 2 min for the right-sided PVs, in order to balance clinical efficacy with the risk of phrenic nerve injury; (4) The minimum cryoablation duration should be 3 min (ideally 4 min) for the left-sided PVs, in order to maximize efficacy; (5) No more than one “bonus freeze” should be delivered.SummaryPractical procedural considerations focused on cryoballoon positioning, pulmonary vein monitoring, and ablation duration can be utilized to optimize patient outcomes and ensure the procedure is safely and effectively performed. More... »
PAGES6
http://scigraph.springernature.com/pub.10.1007/s12170-021-00668-6
DOIhttp://dx.doi.org/10.1007/s12170-021-00668-6
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1136391615
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Center for Cardiovascular Innovation, Vancouver, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Medicine, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Canada",
"Department of Medicine, University of British Columbia, 2775 Laurel St, V5Z 1M9, Vancouver, BC, Canada",
"Center for Cardiovascular Innovation, Vancouver, Canada"
],
"type": "Organization"
},
"familyName": "Andrade",
"givenName": "Jason G.",
"id": "sg:person.0646671363.22",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646671363.22"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s10840-015-0084-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050727555",
"https://doi.org/10.1007/s10840-015-0084-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10840-018-0483-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1109785042",
"https://doi.org/10.1007/s10840-018-0483-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10840-007-9142-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046080974",
"https://doi.org/10.1007/s10840-007-9142-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10840-011-9585-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006213451",
"https://doi.org/10.1007/s10840-011-9585-x"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-03-13",
"datePublishedReg": "2021-03-13",
"description": "Purpose of ReviewAtrial fibrillation (AF) is a chronic and progressive disorder, associated with effort intolerance, impairments in quality of life, and reduced survival. In patients with symptomatic atrial fibrillation, pulmonary vein isolation is an important treatment modality to reduce recurrent arrhythmia and improve quality of life. The purpose of this paper is to review practical considerations of the cryoballoon ablation procedure in order to minimize the risk of adverse procedural outcomes and arrhythmia recurrences.Recent FindingsEmerging evidence with respect to cryoablation dosing has beneficially refined the cryoballoon ablation procedure. In aggregate, dose limitation can be achieved by the following: (1) If real-time pulmonary vein potential (PVP) monitoring is feasible, an early time to isolation (TTI, e.g., < 0\u201360 s) suggests that the \u201cbonus freeze\u201d may be omitted; (2) In PVs where real-time PVP monitoring is feasible, a late TTI (e.g., >60\u201390 s) or a balloon temperature warmer than \u221235 \u00b0C at 60 s suggests that the lesion be abandoned and the balloon repositioned; (3) The minimum cryoablation duration should be 2 min for the right-sided PVs, in order to balance clinical efficacy with the risk of phrenic nerve injury; (4) The minimum cryoablation duration should be 3 min (ideally 4 min) for the left-sided PVs, in order to maximize efficacy; (5) No more than one \u201cbonus freeze\u201d should be delivered.SummaryPractical procedural considerations focused on cryoballoon positioning, pulmonary vein monitoring, and ablation duration can be utilized to optimize patient outcomes and ensure the procedure is safely and effectively performed.",
"genre": "article",
"id": "sg:pub.10.1007/s12170-021-00668-6",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1039476",
"issn": [
"1932-9520",
"1932-9563"
],
"name": "Current Cardiovascular Risk Reports",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"keywords": [
"cryoballoon ablation procedure",
"quality of life",
"arrhythmia recurrence",
"atrial fibrillation",
"bonus freeze",
"ablation procedures",
"adverse procedural outcomes",
"right-sided PVs",
"phrenic nerve injury",
"left-sided PVs",
"symptomatic atrial fibrillation",
"pulmonary vein isolation",
"important treatment modality",
"Recent FindingsEmerging evidence",
"ReviewAtrial fibrillation",
"recurrent arrhythmia",
"cryoballoon ablation",
"effort intolerance",
"vein isolation",
"nerve injury",
"clinical efficacy",
"adverse outcomes",
"treatment modalities",
"procedural outcomes",
"patient outcomes",
"progressive disorder",
"PVP monitoring",
"balloon temperature",
"potential monitoring",
"dose limitation",
"fibrillation",
"recurrence",
"outcomes",
"ablation duration",
"risk",
"procedural considerations",
"efficacy",
"duration",
"patients",
"arrhythmias",
"dosing",
"injury",
"lesions",
"min",
"intolerance",
"impairment",
"disorders",
"survival",
"modalities",
"balloon",
"procedure",
"life",
"ablation",
"monitoring",
"purpose",
"evidence",
"TTI",
"isolation",
"quality",
"early times",
"practical considerations",
"consideration",
"time",
"positioning",
"limitations",
"PV",
"freeze",
"order",
"method",
"respect",
"aggregates",
"paper",
"temperature"
],
"name": "Methods to Optimize Cryoballoon Ablation for Atrial Fibrillation to Minimize Risk of Adverse Outcomes and Arrhythmia Recurrences",
"pagination": "6",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1136391615"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12170-021-00668-6"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12170-021-00668-6",
"https://app.dimensions.ai/details/publication/pub.1136391615"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:31",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_899.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12170-021-00668-6"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12170-021-00668-6'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12170-021-00668-6'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12170-021-00668-6'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12170-021-00668-6'
This table displays all metadata directly associated to this object as RDF triples.
149 TRIPLES
22 PREDICATES
102 URIs
90 LITERALS
6 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s12170-021-00668-6 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1102 |
3 | ″ | schema:author | Ne8912d952b524c289215ed52d8ae0cdb |
4 | ″ | schema:citation | sg:pub.10.1007/s10840-007-9142-9 |
5 | ″ | ″ | sg:pub.10.1007/s10840-011-9585-x |
6 | ″ | ″ | sg:pub.10.1007/s10840-015-0084-3 |
7 | ″ | ″ | sg:pub.10.1007/s10840-018-0483-3 |
8 | ″ | schema:datePublished | 2021-03-13 |
9 | ″ | schema:datePublishedReg | 2021-03-13 |
10 | ″ | schema:description | Purpose of ReviewAtrial fibrillation (AF) is a chronic and progressive disorder, associated with effort intolerance, impairments in quality of life, and reduced survival. In patients with symptomatic atrial fibrillation, pulmonary vein isolation is an important treatment modality to reduce recurrent arrhythmia and improve quality of life. The purpose of this paper is to review practical considerations of the cryoballoon ablation procedure in order to minimize the risk of adverse procedural outcomes and arrhythmia recurrences.Recent FindingsEmerging evidence with respect to cryoablation dosing has beneficially refined the cryoballoon ablation procedure. In aggregate, dose limitation can be achieved by the following: (1) If real-time pulmonary vein potential (PVP) monitoring is feasible, an early time to isolation (TTI, e.g., < 0–60 s) suggests that the “bonus freeze” may be omitted; (2) In PVs where real-time PVP monitoring is feasible, a late TTI (e.g., >60–90 s) or a balloon temperature warmer than −35 °C at 60 s suggests that the lesion be abandoned and the balloon repositioned; (3) The minimum cryoablation duration should be 2 min for the right-sided PVs, in order to balance clinical efficacy with the risk of phrenic nerve injury; (4) The minimum cryoablation duration should be 3 min (ideally 4 min) for the left-sided PVs, in order to maximize efficacy; (5) No more than one “bonus freeze” should be delivered.SummaryPractical procedural considerations focused on cryoballoon positioning, pulmonary vein monitoring, and ablation duration can be utilized to optimize patient outcomes and ensure the procedure is safely and effectively performed. |
11 | ″ | schema:genre | article |
12 | ″ | schema:inLanguage | en |
13 | ″ | schema:isAccessibleForFree | false |
14 | ″ | schema:isPartOf | N127495aa855e46dd8bd1cd399d45bd90 |
15 | ″ | ″ | Nc9e7e64ef3a741dfb929d984a9222f74 |
16 | ″ | ″ | sg:journal.1039476 |
17 | ″ | schema:keywords | PV |
18 | ″ | ″ | PVP monitoring |
19 | ″ | ″ | Recent FindingsEmerging evidence |
20 | ″ | ″ | ReviewAtrial fibrillation |
21 | ″ | ″ | TTI |
22 | ″ | ″ | ablation |
23 | ″ | ″ | ablation duration |
24 | ″ | ″ | ablation procedures |
25 | ″ | ″ | adverse outcomes |
26 | ″ | ″ | adverse procedural outcomes |
27 | ″ | ″ | aggregates |
28 | ″ | ″ | arrhythmia recurrence |
29 | ″ | ″ | arrhythmias |
30 | ″ | ″ | atrial fibrillation |
31 | ″ | ″ | balloon |
32 | ″ | ″ | balloon temperature |
33 | ″ | ″ | bonus freeze |
34 | ″ | ″ | clinical efficacy |
35 | ″ | ″ | consideration |
36 | ″ | ″ | cryoballoon ablation |
37 | ″ | ″ | cryoballoon ablation procedure |
38 | ″ | ″ | disorders |
39 | ″ | ″ | dose limitation |
40 | ″ | ″ | dosing |
41 | ″ | ″ | duration |
42 | ″ | ″ | early times |
43 | ″ | ″ | efficacy |
44 | ″ | ″ | effort intolerance |
45 | ″ | ″ | evidence |
46 | ″ | ″ | fibrillation |
47 | ″ | ″ | freeze |
48 | ″ | ″ | impairment |
49 | ″ | ″ | important treatment modality |
50 | ″ | ″ | injury |
51 | ″ | ″ | intolerance |
52 | ″ | ″ | isolation |
53 | ″ | ″ | left-sided PVs |
54 | ″ | ″ | lesions |
55 | ″ | ″ | life |
56 | ″ | ″ | limitations |
57 | ″ | ″ | method |
58 | ″ | ″ | min |
59 | ″ | ″ | modalities |
60 | ″ | ″ | monitoring |
61 | ″ | ″ | nerve injury |
62 | ″ | ″ | order |
63 | ″ | ″ | outcomes |
64 | ″ | ″ | paper |
65 | ″ | ″ | patient outcomes |
66 | ″ | ″ | patients |
67 | ″ | ″ | phrenic nerve injury |
68 | ″ | ″ | positioning |
69 | ″ | ″ | potential monitoring |
70 | ″ | ″ | practical considerations |
71 | ″ | ″ | procedural considerations |
72 | ″ | ″ | procedural outcomes |
73 | ″ | ″ | procedure |
74 | ″ | ″ | progressive disorder |
75 | ″ | ″ | pulmonary vein isolation |
76 | ″ | ″ | purpose |
77 | ″ | ″ | quality |
78 | ″ | ″ | quality of life |
79 | ″ | ″ | recurrence |
80 | ″ | ″ | recurrent arrhythmia |
81 | ″ | ″ | respect |
82 | ″ | ″ | right-sided PVs |
83 | ″ | ″ | risk |
84 | ″ | ″ | survival |
85 | ″ | ″ | symptomatic atrial fibrillation |
86 | ″ | ″ | temperature |
87 | ″ | ″ | time |
88 | ″ | ″ | treatment modalities |
89 | ″ | ″ | vein isolation |
90 | ″ | schema:name | Methods to Optimize Cryoballoon Ablation for Atrial Fibrillation to Minimize Risk of Adverse Outcomes and Arrhythmia Recurrences |
91 | ″ | schema:pagination | 6 |
92 | ″ | schema:productId | N1c781f9747514b62a1ec81459884f40f |
93 | ″ | ″ | Nbfaf2d8b34c34eec97e1c30f4d956c38 |
94 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1136391615 |
95 | ″ | ″ | https://doi.org/10.1007/s12170-021-00668-6 |
96 | ″ | schema:sdDatePublished | 2022-05-10T10:31 |
97 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
98 | ″ | schema:sdPublisher | Na97d1f75452c4348ae9ff1e0befff7bb |
99 | ″ | schema:url | https://doi.org/10.1007/s12170-021-00668-6 |
100 | ″ | sgo:license | sg:explorer/license/ |
101 | ″ | sgo:sdDataset | articles |
102 | ″ | rdf:type | schema:ScholarlyArticle |
103 | N127495aa855e46dd8bd1cd399d45bd90 | schema:volumeNumber | 15 |
104 | ″ | rdf:type | schema:PublicationVolume |
105 | N1c781f9747514b62a1ec81459884f40f | schema:name | dimensions_id |
106 | ″ | schema:value | pub.1136391615 |
107 | ″ | rdf:type | schema:PropertyValue |
108 | Na97d1f75452c4348ae9ff1e0befff7bb | schema:name | Springer Nature - SN SciGraph project |
109 | ″ | rdf:type | schema:Organization |
110 | Nbfaf2d8b34c34eec97e1c30f4d956c38 | schema:name | doi |
111 | ″ | schema:value | 10.1007/s12170-021-00668-6 |
112 | ″ | rdf:type | schema:PropertyValue |
113 | Nc9e7e64ef3a741dfb929d984a9222f74 | schema:issueNumber | 4 |
114 | ″ | rdf:type | schema:PublicationIssue |
115 | Ne8912d952b524c289215ed52d8ae0cdb | rdf:first | sg:person.0646671363.22 |
116 | ″ | rdf:rest | rdf:nil |
117 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
118 | ″ | schema:name | Medical and Health Sciences |
119 | ″ | rdf:type | schema:DefinedTerm |
120 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
121 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
122 | ″ | rdf:type | schema:DefinedTerm |
123 | sg:journal.1039476 | schema:issn | 1932-9520 |
124 | ″ | ″ | 1932-9563 |
125 | ″ | schema:name | Current Cardiovascular Risk Reports |
126 | ″ | schema:publisher | Springer Nature |
127 | ″ | rdf:type | schema:Periodical |
128 | sg:person.0646671363.22 | schema:affiliation | grid-institutes:None |
129 | ″ | schema:familyName | Andrade |
130 | ″ | schema:givenName | Jason G. |
131 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646671363.22 |
132 | ″ | rdf:type | schema:Person |
133 | sg:pub.10.1007/s10840-007-9142-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1046080974 |
134 | ″ | ″ | https://doi.org/10.1007/s10840-007-9142-9 |
135 | ″ | rdf:type | schema:CreativeWork |
136 | sg:pub.10.1007/s10840-011-9585-x | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1006213451 |
137 | ″ | ″ | https://doi.org/10.1007/s10840-011-9585-x |
138 | ″ | rdf:type | schema:CreativeWork |
139 | sg:pub.10.1007/s10840-015-0084-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1050727555 |
140 | ″ | ″ | https://doi.org/10.1007/s10840-015-0084-3 |
141 | ″ | rdf:type | schema:CreativeWork |
142 | sg:pub.10.1007/s10840-018-0483-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1109785042 |
143 | ″ | ″ | https://doi.org/10.1007/s10840-018-0483-3 |
144 | ″ | rdf:type | schema:CreativeWork |
145 | grid-institutes:None | schema:alternateName | Center for Cardiovascular Innovation, Vancouver, Canada |
146 | ″ | schema:name | Center for Cardiovascular Innovation, Vancouver, Canada |
147 | ″ | ″ | Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada |
148 | ″ | ″ | Department of Medicine, University of British Columbia, 2775 Laurel St, V5Z 1M9, Vancouver, BC, Canada |
149 | ″ | rdf:type | schema:Organization |